Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
PHI applies for listing on OTCQB in the United States
PHI is pursuing a dual listing on the US-based OTCQB Venture Market to provide US-based investors with the ability to invest in PHI. PHI aims to solidify further its presence in the major US market and within regenerative medicine, a rapidly evolving field, spearheaded by the United States globally. The application process has been initiated, and PHI expects to receive approval in the third quarter of 2024.
Interim Report 4 2023/24
This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
BioStock: PHI grows its network of collaborations
BioStock caught up with PHI’s CEO Patrik Eschricht to ask about his outlook for the growing number of academic collaborations and sales partnerships.
PHI bolsters Nordic sales presence with new distribution agreement between Altium and Kem-En-Tec Nordic
PHI is pleased to announce a new distribution agreement between its global distribution partner, Altium, and Kem-En-Tec Nordic, a lab supplier dedicated to supporting BioScience labs in Denmark, Sweden, Norway, Finland and Iceland.
PHI expands to Spanish and Portuguese markets through Altium’s new subcontract with Paralab
PHI is pleased to announce a strategic expansion into the Spanish and Portuguese markets, facilitated by a new subcontract between its global distribution partner, Altium, and Paralab.
PHI partners with University College London to use HoloMonitor in a first clinical research project
PHI is excited to announce a strategic partnership with University College London (UCL). Under this collaboration, PHI will lend a HoloMonitor® M4FL system for use in an ongoing research project at UCL, which runs alongside a clinical trial. This partnership represents PHI’s first direct step in a hospital setting to explore the clinical applications of its innovative technology.
PHI terminates agreement regarding liquidity provider
PHI today announces that the Company has terminated the liquidity provider agreement with Pareto Securities AB. The agreement will expire on July 31, 2024.
HoloMonitor User Spotlight: Besa Xhabija
Dr. Besa Xhabija, Assistant Professor at the University of Michigan-Dearborn, shares how she integrates quantitative live cell imaging using HoloMonitor and AI tools in her cancer research.
BioStock: PHI “It’s the right moment to capitalize on regenerative medicine momentum.”
BioStock contacted CEO Patrik Eschricht for an update on the company’s progress and how PHI will capitalize on the current momentum.
PHI secures a loan facility of in total SEK 7 million
PHI announces that the Company has secured a loan facility of in total SEK 7 million from Bizcap AB, and from that loan facility decided to draw a tranche of SEK 4.5 million.